Introduction
Leading biotechnology firm completed enrollment of 10,335 participants for Phase III trial of a tetravalent dengue vaccine, expected to become India’s first single-shot dengue vaccine by 2027.
Also Read: Sahaj Solar: Stock jump after reporting ₹198.21 Cr revenue in 9M FY26, growth 11.22%
Share price movement of Panacea Biotec
On January 8, 2026, Panacea Biotec Ltd opened at ₹402.90, up 5.14% from its previous close of ₹383.70. The stock reached a high of ₹422.30 (10.06%) and a low of ₹397.35 (3.57%). By 1:06 PM, it traded at ₹403.95, a 5.28% increase, with a market cap of ₹2,474.22 crore.
Panacea Biotec Completes Enrollment for DengiAll® Phase III Trial
Panacea Biotec Limited completed enrollment of 10,335 participants in the Phase III clinical trial of its tetravalent dengue vaccine, DengiAll®, conducted in collaboration with ICMR in India.
Participants will be monitored for two years to assess vaccine efficacy and immunogenicity. DengiAll® is expected to become India’s first indigenous single-shot dengue vaccine, with market entry anticipated by 2027.
Stock performance of Panacea Biotec for Period of 1 week, 6 months, and 1 year
Panacea Biotec Ltd delivered a 1.69% return over the past week, -7.71% over the past six months, and -14.3% over the past one year.
Also Read: Titan jumps 5% after strong 40% YoY growth in Q3 FY26, adds 56 stores
Shareholding pattern of Panacea Biotec
| Particulars | Sep 2025 | Jun 2025 | Mar 2025 |
| Promoter | 72.50% | 72.50% | 72.50% |
| FII | 1.10% | 0.80% | 1.20% |
| DII | 1.80% | 2% | 2% |
| Public | 24.70% | 25.20% | 24.90% |
About Panacea Biotec
Panacea Biotec Ltd (NSE: PANACEABIO), incorporated in 1984, develops, manufactures, and markets vaccines, pharmaceuticals, nutraceuticals, and nutrition products, supplying WHO-prequalified vaccines to over 50 countries.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Panacea Biotec Ltd share price rising today?
A: Panacea Biotec completes enrollment of 10,335 participants for Phase III trial of DengiAll®, India’s first single-shot dengue vaccine, expected by 2027.
Q: What is Panacea Biotec Ltd’s main business focus?
A: Panacea Biotec Ltd develops, manufactures, and markets vaccines, pharmaceutical formulations, nutraceuticals, and nutrition products in India and globally.
Q: What is the 52-week high and low of Panacea Biotec Ltd stock?
A: Panacea Biotec Ltd stock’s 52-week high is ₹581.00 and low is ₹282.15.
